Efficacy and Safety of Rituximab Second-Line Therapy for Membranous Nephropathy: A Prospective, Matched-Cohort Study
Paolo Cravedi(Icahn School of Medicine at Mount Sinai), Piero Ruggenenti(Mario Negri Institute for Pharmacological Research), Maria Chiara Sghirlanzoni(Azienda Ospedaliero-Universitaria delle Marche), Maddalena Marasà(Azienda Ospedaliero-Universitaria delle Marche), Giuseppe Remuzzi(Mario Negri Institute for Pharmacological Research), Alessandra Salerno(University of Palermo)
Cited by 71
Related Papers
von Willebrand Factor–Cleaving Protease in Thrombotic Thrombocytopenic Purpura and the Hemolytic–Uremic Syndrome
|New England Journal of Medicine|1998|1.7k
Bardoxolone Methyl in Type 2 Diabetes and Stage 4 Chronic Kidney Disease
|New England Journal of Medicine|2013|990
Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria
|The Lancet|1999|909
Overview of Complement Activation and Regulation
|Seminars in Nephrology|2013|864